BASIC AND CLINICAL STUDIES ON SULBACTAM/CEFOPERAZONE

Abstract

We investigated the bacteriological and clinical effects of a new formulation, Sulbactam/Cefoperazone, in which cefoperazone was combined in a ratio of 1: 1 with Sulbactam, a β-lactamase inhibitor developed by Pfizer Inc., USA, and obtained the following results.
1. The peak values of MIC distributions of Sublactam/Cefoperazone against clinical isolates are 1.56μg/ml for S. aureus, 0.78-1.56μg/ml for E. coli, 0.2μg/ml for K. pneumoniae, 0.78μg/ml for P. mirabilis, 0.39μg/ml for P. vulgaris, and 6.25μg/ml for P. aeruginosa, respectively. While no effects of the combination of cefoperazone with sulbactam were obvious against S. aureus, E. coli and P. aeruginosa, the antibacterial activities of Sulbactam/Cefoperazone against K. pneumoniae, P. mirabilis and P. vulgaris were superior to those of cefoperazone alone, demonstrating the synergistic effects of the combination against these species.
2. Sulbactam/Cefoperazone was administered by drip infusion at 1-3g, twice daily for 2 to 27 days to a total of 7 patients, 4 cases of respiratory tract infections, 2 cases of septicemia and 1 case of infected diabetic gangrene. The clinical efficacy was effective in 3 cases, ineffective in 2 cases and 2 cases in inevaluable. Transient aggravation of liver functions were observed in 2 cases.